China’s Aland Health is exploring a potential sale and has begun seeking buyers at a valuation exceeding $1.5 billion, according to people familiar with the matter.
The privately held health supplements maker has reportedly engaged financial advisers to sound out interest from both domestic and international investors, the sources told Reuters, requesting anonymity because the discussions are private.
Aland Health, known for its vitamins, minerals, and dietary supplements, has expanded rapidly in recent years, capitalising on growing demand for health and wellness products in China and abroad. The company operates manufacturing facilities in several provinces and exports to over 50 countries.
Industry insiders say a sale could attract interest from multinational nutrition and pharmaceutical companies looking to strengthen their footprint in Asia, as well as private equity firms seeking exposure to China’s expanding health products market.
“The valuation reflects both the company’s strong brand position and the sector’s high growth potential,” one source familiar with the talks said. “However, regulatory scrutiny and shifting consumer trends will be key factors for any buyer.”
Aland Health has not publicly commented on the potential deal, and it remains unclear whether the process will lead to a full sale, a partial stake transaction, or an initial public offering if a buyer is not secured.
The Chinese health supplements market is forecast to grow at a compound annual rate of over 6% through 2030, driven by rising disposable incomes, an ageing population, and increasing health awareness, according to market research firm Euromonitor International.
If completed, the sale would be one of the largest transactions in China’s nutrition and wellness industry in recent years, underscoring the sector’s resilience despite broader economic headwinds.